化学療法科
研究実績
学会発表
演題名 | 演者 | 発表年月日 | 学会名 |
---|---|---|---|
肝内胆管癌を中心とした胆道癌におけるFGFR2融合遺伝子の頻度と臨床病理学的特徴:前向き観察研究(PRELUDE 研究) | 上野 誠 et al. 行澤斉悟(共同演者) |
2020.1.11 | 第21回日本肝がん分子標的治療研究会 |
DS-SCREEN: prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer population | Ishigami m Yukisawa S et al.(共同発表) |
2020.1.21 | Gastrointestinal Cancers Symposium 2020 |
The results of Japanese subgroupanalyses from TAGS: a phase 3study of FTD/TP(I TAS-102) in heavily pretreatedmGC | Hosokawa A Yukisawa S et al.(共同発表) |
2019.7.20 | 日本臨床腫瘍学会 |
FGFR2-fusion gene in biliary tractcarcinomas: a prospective observationalstudy(PRELUDE study) | Morizane C Yukisawa S et al.(共同発表) |
2019.7.20 | 日本臨床腫瘍学会 |
原著論文・著書
論文名 | 著者 | 発表年 | 掲載誌名 |
---|---|---|---|
Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastiric cancer populations: DS-Screen Study | Hisateru Yasui Atsushi Takeno Hiroki Hara Hiroshi Imamura Hiroki Akamatsu Kazumasa Fujitani Minoru Nakane Chihiro Nakayama Kondoh Seigo Yukisawa Junichiro Nasu Yoshinori Miyata Akitaka Makiyama Hiroyasu Ishida Norimasa Yoshida Eiji Matusumura Masato Ishigami Masahiro Sugihara Atusshi Ochiai Toshihiko Doi |
2022 | Int J Coorectal Dis.2022;37(6):1393-1402 |
Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study(PRELUDE Study) | Maruki Y Morizane C Yukisawa S et al. |
2021.3 | J Gastroenterol. |
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer:The FUGA-BT( JCOG1113) Randomized Phase III Clinical Trial. | Morizane C Yukisawa S et al.(共著) |
2019 | Annals of Oncology 30(12):1950-1958 |